reason report
dupi miss-inventori demand trend intact
revenu averag fx
recent regeneron consensu previou
estim us sale ex-u
sale base announc
adjust revenu forecast downward regeneron ahead
week earn call kevzara praluent also
weaker expect highli like regeneron
report rare larg cap biotech miss result regeneron
stock pull back much friday close
anticip neg event revenu weak
disappoint channel inventori reduct difficult
explain underli rx trend remain strong dupix
trim forecast somewhat maintain rel
bullish view product long-term outlook howev
continu dysfunct sanofi-regeneron relationship
becom liabil investor regeneron stock
investor like limit patienc surpris
dupix disappoint product praluent
last friday call boost investor excit
outlook partner product even futur
valu joint enterpris mp
checkmat regn/sni kevzara start slowli
dupix stumbl sign commerci misstep
becom difficult ignor
inventori drawdown discount caus major
weak sanofi highlight larg dupix
headwind us quarter explan weaker-
than-expect sale result sequenti lower sale vs
two-third due inventori draw-down week drug
week one-third due higher patient assist discount
typic neither sanofi regeneron manag indic
elev dupix channel inventori consensu
estim fail account effect adjust effect
improv contribut ex us market would deliv
signific revenu beat vs us consensu unlik
impress investor underli demand trajectori dupix
appear strong volum increas sequenti
steadi patient continu initi dupix week
averag price-to-earnings p/ dcf
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm dilut ep non-gaap
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
leerink dupix forecast reduc base quarter result
lower dupix forecast total forecast
declin remain
lower compar consensu us revenu forecast
reduc slightli forecast ex us sale
larg unchang continu expect product
ramp strongli acceler basi
expect asthma approv given
proxim earn addit commentari manag
maintain price target rate
price target regeneron stock rate outperform regeneron
veteran biopharmaceut compani come initi base portfolio fast-
follow second entrant rapidli grow biopharmaceut market first product eylea
continu surpris investor taken grow market intraocular
vegf vascular endotheli growth factor antibodi treatment eylea contribut nearli
global sale trump categori pioneer roch lucenti well
cheaper altern bevacizumab remain posit eylea expect continu
grow lose market share emerg competitor
abicipar like view gain approv excit aspect compani
next wave innov antibodi notabl dupix await approv
first like multipl allerg diseas indic expect dupix
dupilumab gener revenu signific upsid
indic longer term regeneron wholli own antibodi could contribut
meaning revenu earn growth period current compani
invest mode result earn cash flow convers revenu lag peer
industri anticip cash flow true earn improv
period profit antibodi collabor sanofi begin accumul
dupix sale consensu sanofi report global dupix
sale sale split us ex-u base
averag euro-usd exchang rate estim regeneron report global
sale us sale ex-u sale current regeneron
consensu expect vari wide sourc prior estim
regardless sourc use dupix sale significantli recent
dupix headwind due inventori higher season discount sanofi
indic dupix experienc sequenti headwind two-third
headwind due inventori draw-down week drug stock week drug
stock week close normal inventori level launch product expect
lost sale reflect futur quarter one-third attribut higher
discount patient assist program common immunolog medicin
us patient experi deduct reset chang insur plan expect
increment gross net co-pay assist disappear
later period bulk cost annual deduct re-set complet exist
dupix underli demand remain consist high signific
adjust due report headwind import disclosur continu
strong underli demand dynam dupix sanofi state dupix prescript
grew sequenti patient continu start therapi week sanofi also
indic patient enter therapi mix moder sever patient
sever patient initi treatment suggest treatment
penetr widen among dermatologist howev follow-up initi
patient launch sanofi estim dupix treatment persist
previous disclos expect origin set
manag sanofi remain confid therapi persist dupix remain higher
common immunomodulatori immunosuppress biolog drug sanofi also
indic past quarter contract dynam us payer remain stabl
sanofi regeneron believ commerci live access dupix
coverag polici match dupix label requir step-edit one prior
topic drug failur recent research link suggest reimburs coverag remain
challeng certain patient physician bullish comment access
sanofi call reflect recent medacorp survey provid
underli demand trend still point robust launch persist remain
steadi sanofi indic estim persist rate fell approxim
long-term patient experi accumul estim adjust
us sale result plu headwind deriv new
patient start deriv legaci patient assum constant rate
weekli new patient addit provid quarter includ annual therapi
persist legaci patient new cohort patient begin
calcul us dupix sale could assum
compar consensu conserv updat estim
estim also includ potenti two month us sale asthma dupix
us pdufa action date octob could add revenu plu
potenti inventori stock worryingli sanofi bare mention approv revenu
potenti confer call
price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg molecul biopharmaceut compani price
sale multipl larg cap high growth compani discount cash flow dcf use
averag larg cap larg molecul therapeut compani nvo
earn multipl ep appli current ep estim
give valu use high growth revenu multipl similar compani
nvo consensu sale appli revenu
estim give valu lastli dcf valuat given wacc
termin cash flow growth rate give present valu averag
three method current price target upon complet analysi quarterli
result revisit price target present remain unchang
risk view outlook valuat regeneron includ major chang price
reimburs coverag label competit posit eylea compani main
product today risk includ commerci develop disappoint compani
next partner program launch dupix kevzara well continu weak
demand compani cholesterol treatment praluent subsequ releas
cardiovascular outcom data regeneron fail match cardiovascular outcom
demonstr rival product would advers affect
revenu outlook valuat lastli compani convert rel littl
revenu cash flow today histori return cash investor ultim
may undermin valu stock investor willing continu
million
leerink partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink partner target regeneron
method high growth larg cap growth biotech ep multipl
current larg cap larg molecul therapeut compani multipl
leerink partner forma ep estim
impli price ep
equiti
number period
method larg cap growth biopharma forward multipl enu
discount
larg cap high growth biopharma price/sal multipl nvo
leerink partner revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
leerink partner research compani file factset
million
leerink partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink partner target regeneron
method high growth larg cap growth biotech ep multipl
current larg cap larg molecul therapeut compani multipl
leerink partner forma ep estim
impli price ep
equiti
number period
method larg cap growth biopharma forward multipl enu
discount
larg cap high growth biopharma price/sal multipl nvo
leerink partner revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
leerink partner research compani file factset
